CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel ...

Protecting native maize diversity is one of the key arguments behind Mexico’s constitutional ban on genetically modified corn ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.66, moving +1.88% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq ...

Using a modified CRISPR-based mechanism, the team led by Prof. Pallob Kundu has developed a stress-activated gene switch that empowers plants to survive extreme heat and microbial attacks.

Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

Japanese researchers have successfully eliminated the extra chromosome responsible for Down syndrome using CRISPR gene ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations ...

A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each ...

The projected fair value for CRISPR Therapeutics is US$83.24 based on 2 Stage Free Cash Flow to Equity CRISPR Therapeutics' US$45.55 share price signals that it might be 45% undervalued The analyst ...

Back in 1900 the life expectancy of people with Down Syndrome was 9 years. In 1984, it was 28 years, today it's leveled off ...